Targeting MDSCs for cancer therapy involves several strategies. One approach is to inhibit the recruitment and differentiation of MDSCs using agents that block specific signaling pathways, such as STAT3 inhibitors. Another strategy is to deplete MDSCs using chemotherapeutic agents or antibodies that target MDSC-specific markers. Additionally, reprogramming MDSCs to lose their immunosuppressive functions or enhancing the immune response to counteract MDSC activity are also potential therapeutic approaches.
